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Prostaglandin G/H synthases (PGHS), commonly referred to as cyclooxygenases (COX-1 and COX-2), catalyze a key step in the synthesis of
biologically active prostaglandins (PGs), the conversion of arachidonic acid (AA) into prostaglandin H2 (PGH2). PGs have important functions in
a variety of physiologic and pathologic settings, including inflammation, cardiovascular homeostasis, reproduction, and carcinogenesis. However,
an evaluation of prostaglandin function in early development has been difficult due to the maternal contribution of prostaglandins from the uterus.
The emergence of zebrafish as a model system has begun to provide some insights into the roles of this signaling cascade during vertebrate
development. In zebrafish, COX-1 derived prostaglandins are required for two distinct stages of development, namely during gastrulation and
segmentation. During gastrulation, PGE2 signaling promotes cell motility, without altering the cell shape or directional migration of gastrulating
cells. During segmentation, COX-1 signaling is also required for posterior mesoderm development, including the formation of vascular tube
structures, angiogenesis of intersomitic vessels, and pronephros morphogenesis. We propose that deciphering the role for prostaglandin signaling
in zebrafish development could yield insight and ultimately address the mechanistic details underlying various disease processes that result from
perturbation of this pathway.
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Prostanoids, comprised of prostaglandins (PGs) and throm-
boxanes (TXs), are oxygenated metabolites of C20 polyunsat-
urated fatty acids including arachidonic and eicosapentaenoic
acids that are released from membrane phospholipids. Prosta-
glandins have been shown to play important roles in various
physiological processes in invertebrates (Rowley et al., 2005;
Stanley, 2000), vertebrates (Cha et al., 2005; Evans and
Gunderson, 1998; Grosser et al., 2002; Yang et al., 2002), and
mammals (Langenbach et al., 1999; Narumiya et al., 1999),
indicating that these bioactive lipid molecules are evoluntiona-
rily conserved. Until now, most of the studies evaluating0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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Analyses of genetic knockouts of cyclooxygenases and prosta-
glandin signaling components have led to significant progress in
this field. This review will summarize the recent advances in the
field of prostaglandin biology with a particular focus on the
developmental role of these lipid mediators. In addition, we
propose that zebrafish may provide a very useful model system
to elucidate the precise role of prostaglandin signaling pathways
and their biological endpoints in early development.
Historical perspective
Discovery of prostanoids
Seminal work in understanding the prostaglandin biosyn-
thetic pathway came to light by elucidating the mechanism by
which aspirin exerts its anti-inflammatory, analgesic, and89 (2006) 263 – 272
www.e
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and other non-steroidal anti-inflammatory drugs (NSAIDs)
inhibit the activity of the enzyme now known as cyclooxy-
genase (COX), leading to the formation of prostaglandins
(PGs) that cause inflammation, swelling, pain, and fever (Vane,
1971). Since this discovery there has been a fervent interest in
understanding how cyclooxygenase signaling functions in both
physiological and pathophysiological conditions.
Long before we knew how aspirin worked, Kurzrok and
Lieb (1930) first determined there was some biologic activity
in semen when they observed violent contractions of the uterus
following artificial insemination. In 1933 Goldblat reported
that human semen contained a substance that both reduced
blood pressure and stimulated smooth muscle (Goldblatt, 1933,
1935). At about the same time, von Euler and colleagues
showed that a lipid soluble factor from semen could decrease
blood pressure and stimulate smooth muscle contractions as
well (Euler, 1935). He named this substance ‘‘prostaglandins’’
assuming that it came from the prostate gland. Later, others
were to find that this was not the case.
In the 1950s, Bergstro¨m, et al., made a breakthrough in the
field by purifying the chemical compound of two major
prostaglandins, PGE and PGF. He subsequently demonstrated
that prostaglandins are formed from unsaturated fatty acids,
primarily from arachidonic acid (Bergstrom, 1967). In the
1960s, work by Samuelsson revealed the processes by which
prostaglandins are metabolized and demonstrated the existence
of two distinct pathways originating from arachidonic acid, one
pathway leading to prostanoid formation, the other to the
formation of leukotrienes (Bergstroem and Samuelsson, 1965).
Not only did Vane’s discovery lead to an improved
understanding of how prostaglandins are synthesized, he
provided the mechanistic insight that the NSAIDs bind directly
to cyclooxygenase to inhibit prostaglandin production (Vane,
1971). The mechanism of NSAID action was to either bind
covalently to the active sites (aspirin) or to compete with
substrate for the binding to the active site (most of the other
NSAIDs) of the cyclooxygenase enzyme. In 1982, ‘‘for their
discoveries concerning prostaglandins and related biologically
active substances,’’ Bergstro¨m, Samuelsson, and Vane shared
the Nobel prize in Medicine (Raju, 1999).
Discovery of cyclooxygenase
Subsequently, extensive advances in molecular biology led to
the isolation of Cox-1 cDNA, corresponding to a genetic locus
that spanned 11 exons, covered 25 kb, and encoded a 2.8–3.0 kb
mRNA and 68-kDa protein (Yokoyama et al., 1988). Interest-
ingly, the levels of Cox-1 mRNA did not vary greatly in cell
stimulation experiments. In fact, COX-1 was expressed consti-
tutively in many tissues, including the kidney, lung, stomach,
duodenum, jejunum, ileum, colon, and cecum of the rat, dog,
Rhesus monkey, and human (Kargman et al., 1996). These
findings led to the hypothesis that COX-1 is the ‘‘housekeeping’’
enzyme responsible for basal, constitutive prostaglandin syn-
thesis. For example, prostaglandins such as PGE2 and PGI2
appear critical for maintaining physiologic homeostasis.The existence of a second cyclooxygenase was proposed
when sheep epithelial cells were found to exhibit increased
prostaglandin production following stimulation with growth
factors (Rosen et al., 1989). This also correlated with an
increase in the amount of 4.0 kb mRNA that hybridized with
Cox-1 cDNA. A fervent search commenced to identify a
second cyclooxygenase enzyme, which was reported by at least
three groups. In 1991, Simmons and colleagues identified
COX-2 from src-transformed chicken fibroblasts, and deter-
mined that its sequence was 60–65% similar to that of sheep,
mouse, and human COX-1 protein (Xie et al., 1991). Cox-2
expression was also detected in src-transformed fibroblasts and
in mouse fibroblasts treated with the tumor promoter tetra-
decanoylphorbolacetate (TPA) (Kujubu et al., 1991) and
human endothelial cells or monocytes treated with TPA or
lipopolysaccharide (LPS) (Hla and Neilson, 1992; O’Banion et
al., 1991). Most tissues did not express Cox-2 constitutively,
but various intracellular and extracellular stimuli including
cytokines, mitogens, growth factors, and tumor promoters
could rapidly induce Cox-2 expression in many different cell
lines. Researchers then began to postulate that COX-2 was an
‘‘inducible’’ enzyme that produces prostaglandins in a wide
variety of inflammatory and carcinogenic settings. Hence,
COX-2- selective inhibitors, such as CelebrexR and VioxxR,
were developed to treat various inflammatory diseases and later
evaluated for their potential as chemopreventive agents
(Marnett and DuBois, 2002).
Eicosanoid metabolism
Synthesis of prostanoids is initiated by the rate-limiting
release of arachidonic acid from the plasma membrane by
phospholipase A2. Arachidonic acid is then converted to PGH2
by the enzymatic, two-step action of prostaglandin G/H
synthase-1 or -2 (PGHS), commonly referred to as cycloox-
ygenase-1 and -2 (Fig. 1). COX enzymes reside in the
endoplasmic reticulum (ER) and nuclear membrane with the
substrate-binding pocket precisely orientated to take up the
released arachidonic acid. PGH2 is isomerized by various tissue
specific prostaglandin synthases to form active lipid molecules.
Aside from the prostanoid pathway, arachidonic acid can also
serve as a substrate for the formation of hydroxyeicosatatraenoic
acids (HETEs), leukotrienes, and lipoxins by the action of
lipooxygenase enzymes. A third pathway leads to production of
epoxyarachidonic acid via the enzymatic activity of cytochrome
P450 monooxygenase enzymes. The metabolic products from
the three pathways are collectively known as eicosanoids from
the Greek root of eikosi, meaning ‘‘twenty’’ for the 20-carbon
fatty acid of arachidonate.
The crystal structures of COX-1 and COX-2 are remarkably
similar, with one notable amino acid difference that allows for a
larger ‘‘side-pocket’’ for substrate access in COX-2 (Smith et
al., 2000). PGH2 is subsequently converted to one of several
structurally related prostaglandins, including PGE2, PGD2,
PGF2a, PGI2 (also known as prostacyclin), and TxA2 (throm-
boxane A2), by specific PG synthases (Funk, 2001). The
coupling of PGH2 synthesis to metabolism by downstream
Fig. 1. Prostanoid biosynthetic pathway. NSAIDs are non-selective inhibitors of COX enzymes, while coxibs are selective inhibitors of COX-2. Prostaglandin
synthases are distributed specifically in various tissues, and boxed inset reveals spatial expression of prostaglandin receptors in various tissue types.
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For example, thromboxane synthase is found mainly in
platelets and macrophages, and TxA2 stimulates platelet
aggregation and vessel constriction. Whereas prostacyclin
synthase is expressed in endothelial cells, its product, PGI2,
is known for its cardioprotective properties that cause platelet
de-aggregation and vessel dilation. PGF synthase is found in
the uterus, and two types of PGD synthase are in brain and
mast cells. Two PGE synthases have been described: micro-
somal PGE synthase (mPGES), a member of the MAPEG
(Membrane-Associated Proteins in Eicosanoid and Glutathione
metabolism) family (Schneider et al., 2004), and cytosolic PGE
synthase (cPGES). These two PGESs largely account for PGE2
synthesis (Fig. 1) in mammals.
Signaling downstream of cyclooxygenase in mammals
There are at least 9 known prostaglandin receptors in
mammals, as well as several additional splice variants with
divergent carboxy termini (Narumiya et al., 1999). Four of the
receptor subtypes bind PGE2 (EP1–EP4); two bind PGD2
(DP1 and DP2) and the FP, IP, and TP receptors bind PGF2a,
PGI2, and TxA2, respectively. The prostaglandin receptors are
categorized as three clusters of a distinct subfamily in the G
protein-coupled receptor (GPCR) superfamily of seven
transmembrane-spanning proteins. The lone exception is
DP2, a member of the chemoattractant receptor subgroup.
The ‘‘stimulatory’’ receptors including IP, DP1, EP2, and EP4that signal through Gs-mediated increases in intracellular
cyclic adenosine monophosphate (cAMP) form one cluster
(Hirata et al., 1994a; Honda et al., 1993; Namba et al., 1994;
Regan et al., 1994); the receptors EP1, FP, and TP form a
second group that signals through Gq-mediated increases in
intracellular calcium (Graves et al., 1995; Hirata et al., 1991;
Namba et al., 1993). Lastly, the EP3 receptor is regarded as
an ‘‘inhibitory’’ receptor as it couples to Gi to decrease cAMP
formation (Sugimoto et al., 1992).
Other mechanisms, besides ligand–receptor binding on the
plasma membrane, have been implicated in prostaglandin
signaling. For example, there is evidence that EP receptors
can be internalized into the nucleus (Bhattacharya et al.,
1998, 1999). EP3 and EP4 receptors have been shown to
regulate gene transcription by modulating the release of
calcium from nuclear calcium pools or by activation of
calcium channels (Desai et al., 2000). In addition, prosta-
glandin metabolites have also been shown to activate
transcriptional targets directly by binding to peroxisome
proliferator-activated receptors (PPARs), which are members
of the orphan nuclear receptor superfamily that constitutively
bind to the promoter elements of their target genes (Forman et
al., 1997). PGI2 and PGJ2 (a metabolite product of PGD2)
have been shown to bind PPARy and PPARg, respectively, for
direct activation of transcriptional targets. In view of its
physiologic significance, gaining a detailed understanding of
prostaglandin signaling becomes an especially important area
of research.
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Even with our advanced understanding of prostaglandin
signaling, we have not elucidated the precise role of these
bioactive lipids during embryogenesis. So far, most of the work
in non-mammalian systems has been focused on identification
of functional COX homologues. PGs and other eicosanoids
have been identified in both invertebrates and vertebrates. In
invertebrates, eicosanoids mediate cellular immunity, play a
role in fertility and regulate febrile response (Stanley, 2005).
Although COX-like enzymes have been identified in inverte-
brates, the exact mechanism of prostanoid biosynthesis is still
under debate (Rowley et al., 2005). In vertebrates, a COX-2
homologue has been cloned from rainbow trout (Zou et al.,
1999), and COX-1 and COX-2 homologues were identified
from brook trout (Roberts et al., 2000) and dog fish shark
(Yang et al., 2002). In addition, the zebrafish COXs were
shown to be genetically and functionally similar to the
mammalian counterparts (Grosser et al., 2002), indicating that
the duplication of COX gene likely occurred before the
emergence of cartilaginous fish.
In mice, inactivation of genes encoding COX enzymes via
homologous recombination did not reveal much insight into the
developmental role for prostaglandins. In heterozygous matings,
Cox-1 null mice were born in the expected ratios and lived to a
normal lifespan (Langenbach et al., 1995). Surprisingly, these
mutant mice were quite healthy given the putative ‘‘housekeep-
ing’’ function of the COX-1 enzyme. However, Cox-1 null
female mice demonstrated prolonged gestation periods and
delayed parturition that ultimately resulted in a reduction in the
number of viable progeny. The defective reproduction due to the
loss of COX activity could be suppressed by the administration
of PGF2a (Gross et al., 1998). This line of investigation
suggested that COX-1 function was dispensable for ovulation,
fertilization, and implantation of mouse embryos, but indis-
pensable for fulfilling the normal labor term.
Cox-2 null mice demonstrated numerous developmental
defects (Dinchuk et al., 1995). Only 60% of the pups survived
to weaning, and of those, only 75% survived to 1 year of age.
Death after 3 weeks of age was mainly due to gastric peritonitis
or kidney dysfunction, which suggested that certain somatic
tissues require COX-2 derived prostaglandins for normal
homeostasis. In addition, Cox-2 null females also demonstrated
multiple reproductive defects, including ovulation, fertilization,
implantation, and decidualization, indicating that COX-2
derived prostaglandins are also critical for multiples stages of
reproduction (Lim et al., 1997). Indeed, exogenous PGE2
treatment can rescue the defects in ovulation in COX-2-
deficient mice, demonstrating that proper follicle expansion
and ovulation requires the synthesis of PGE2. Recently, the
reproductive defects associated with Cox-2 inactivation in
C57BL/6J/129 mice was introduced onto CD1 genetic back-
ground that had high endogenous expression of COX-1 in the
reproductive organs (Wang et al., 2004). This showed
functional redundancy between COX enzymes and revealed
that the levels of prostaglandins ultimately determine the
success of reproduction cycle.Prostaglandin receptors and development
Reproduction
The inactivation of genes encoding prostaglandin receptors
by homologous recombination in mice revealed that IP-, EP1-,
EP3-, EP4-, and TP-deficient females were essentially fertile,
birthing embryos that develop normally. However, EP2-null
female mice exhibited multiple reproductive defects similar to
COX-2-deficient females (Hizaki et al., 1999; Kennedy et al.,
1999; Tilley et al., 1999), delivering fewer pups than their wild-
type counterparts, irrespective of the genotypes of mating
males. Ovulation was slightly impaired and fertilization
dramatically reduced in EP2-deficient mice, leading to the
hypothesis that the reproductive failure during early pregnancy
in COX-2-deficient mice was due to lack of PGE2 ligands
available to bind to the EP2 receptor (Hizaki et al., 1999).
Gonadotropins induced the expression of EP2 receptor and
COX-2 in the cumulus and elavated PGE2, in turn, stimulated
cumulus expansion by elevating cAMP (Hizaki et al., 1999).
These studies demonstrated that the PGE2 and EP2 receptor
system work as a positive-feedback loop to induce the oophorus
maturation required for fertilization, during and after ovulation.
PGF2a has a well-recognized role for stimulating leuteolysis
and uterine contraction, important for inducing labor and
delivering pups during parturition, respectively. Consistently,
generation of FP-deficient female mice demonstrated that they
do not undergo parturition (Sugimoto et al., 1997). Normally
the luteolytic action of PGF2a is required in mice to diminish
progesterone levels and thus permit the initiation of labor. In
FP null females, production of PGF2a in intrauterine tissues
during late pregnancy is significantly reduced and the
administration of PGF2a on day 19 is able to restore normal
parturition (Sugimoto et al., 1997). The important role of
PGF2a in uterine contraction is supported by studies of COX-1-
deficient female mice, which exhibit a similar defect in
parturition (Gross et al., 1998). In wild-type mice, uterine
expression of Cox-1 mRNA gradually increased from day 15
of pregnancy, reaching maximal levels on day 17 and rapidly
decreasing after day 20, the day when parturition normally
occurs. Ichikawa and colleagues found that these cycles are
altered in FP-deficient mice and the uterine expression of Cox-
1 mRNA was still elevated on day 20 of pregnancy (Tsuboi et
al., 2000). This observation suggested that progesterone
withdrawal could serve as a negative feedback system for
uterine COX-1 expression.
Ductus arteriosus
The ductus arteriosus is a normal fetal structure, allowing
blood to bypass circulation through the lungs, since the fetus
does not require its lungs for oxygenation (oxygen is provided
through the mother’s placenta), and blood flow is shunted from
the left pulmonary artery to the aorta. In most cases, the ductus
closes soon after birth, and its closure is stimulated by
withdrawal of prostaglandins (which act as a dilator) as well
as active contraction exerted by increased oxygen tension
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the ductus, emphasizing the role of prostaglandins in this
process, and indeed, NSAIDs are now used to treat patent
ductus arteriosus in neonates. Conversely, vasodilator PGs such
as PGE1 maintain the patency of the ductus in neonates with
ductus arteriosus (Smith and McGrath, 1994). A study using
various synthetic PG analogs suggested that both IP and EP4
receptors are present in the ductus and are involved in
maintaining the dilation of this vessel (Smith and McGrath,
1994). EP4 receptor expression was confirmed by in situ
hybridization of its mRNA in the mouse (Nguyen et al., 1997).
Although disruption of the mouse IP gene did not appear to
cause any abnormality of the ductus (Murata et al., 1997), mice
without EP4 receptors died within 3 days after birth, due to
marked pulmonary congestion and heart failure (Nguyen et al.,
1997), likely resulting from a patent ductus. Administration of
indomethacin to mice during late pregnancy elicited premature
closure of the ductus in wild-type fetuses, but not in the ductus
of EP4-deficient fetuses, indicating that the dilatory effect of
PGE2 on this vessel is mediated by the EP4 receptor (Nguyen et
al., 1997). This finding is also supported by the phenotype of
COX-1, COX-2 double knockout mice, which died shortly after
birth due to a patent ductus arteriosus (Loftin et al., 2001).
Cardiovascular homeostasis
Perhaps the most clinically recognized aspect of prostaglan-
din biology is its role inmaintaining cardiovascular homeostasis.
PGI2 (prostacyclin) has well-known vasodilating and anti-
thrombogenic properties that confer cardioprotective effects.
PGI2 acts on platelets to inhibit platelet aggregation and on
smooth muscle cells of blood vessels to cause vasodilation.
Analyses of mice deficient in the IP receptor revealed that their
basal blood pressure and heart rate were not different from those
of wild-type siblings (Murata et al., 1997). This result indicated
that the PGI2 and IP receptors do not work constitutively in
regulating the systemic circulation but more likely work on
demand, in response to local stimuli. Furthermore, IP-deficient
mice developed and aged normally, without an increased
occurrence of vascular incidents. However, an enhanced
thrombotic activity was observed in IP-deficient mice in
response to endothelial damage (Murata et al., 1997). These
findings confirmed the proposed role of PGI2 as an endogenous
antithrombotic agent and suggest that this antithrombotic system
is activated in response to vascular injury.
On the other hand, TxA2 also acts on platelets to induce
platelet aggregation and on smooth muscle cells of blood vessel
to cause vasoconstriction. Because of their opposing effects on
blood vessels and platelets, a precise balance between the PGI2
and TxA2 is probably important for maintaining vascular
homeostasis (i.e., to prevent thrombosis and vasospasm while
performing efficient hemostasis). TP-deficient mice showed
increased bleeding tendencies and were resistant to cardiovas-
cular shock induced by intravenous infusion of a TP agonist,
U-46619, and arachidonic acid (Thomas et al., 1998). The
increased bleeding tendency had also been noted in mice
harboring in the TP receptor an arginine to leucine missensemutation, which impairs coupling of the mutant receptor to Gq
(Hirata et al., 1994b). Platelets from patients homozygous for
this mutation showed no aggregation in response to TxA2.
These results supported the notion that the TxA2 and TP
receptor signaling do indeed play a physiological role in
regulating hemostasis.
PGE2 signaling also acts on smooth muscle cells of the
vasculature to regulate blood pressure. To understand which EP
receptor is responsible for vessel contraction, Breyer and
colleagues administered PGE2 and PGE analogs intravenously
into wild-type and EP2-deficient mice and examined the in vivo
response (Kennedy et al., 1999). They observed that infusion of
PGE2 or an EP2 agonist, butaprost, induced a transient
hypotension in wild-type mice, whereas injection of the mixed
EP1/3 agonist, sulprostone, resulted in an increase in arterial
blood pressure. The hypotensive response to butaprost was not
observed in EP2-deficient mice, although the hypertensive
effects of sulprostone persisted. Surprisingly, PGE2 also evoked
considerable hypertension in EP2-deficient mice. The authors
suggested that the absence of the EP2 receptor abolishes the
ability of the mouse vasculature to vasodilate in response to
PGE2 and unmasked a contractile response mediated via
interaction with the vasoconstrictor EP receptor(s). Interesting-
ly, when fed a high-salt diet, the EP2-deficient mice developed
significant hypertension with a concurrent increase in urinary
excretion of PGE2. These results indicated that PGE2 is
produced in the body in response to a high-salt diet to decrease
blood pressure via the relaxant EP2 receptor and that
perturbation of this pathway may be involved in the develop-
ment of salt-sensitive hypertension. Coffman and colleagues
compared the roles of individual EP receptors in males and
females (Audoly et al., 1999) and found that the relative
contributions of each EP receptor subtype were strikingly
different. In females, the EP2 and EP4 receptors mediated the
major portion of the vasodepressor response to PGE2. However
in males, the EP2 receptor had a modest role and most of the
vasodepressor effect were mediated by the EP1 receptor coupled
to phospholipase C. In addition, the EP3 receptor in male mice
actively opposed the vasodepressor actions of PGE2. Thus the
genetic evidence points to a complex interplay of EP, TP, and IP
receptors in regulating cardiovascular homeostasis in mammals.
Given this knowledge about prostaglandin biology in the
murine model, can we address a role for COX signaling in
embryonic development? The answer is decidedly negative. In
the mouse, the maternal contribution of prostaglandins to COX-
mutant embryos and the severe defects of the reproductive
capacity of COX-deficient female mice, severely hindered the
studies of the developmental role for prostaglandins free from
maternal interference. It has been hypothesized that the
maternal contribution of prostaglandins in the placenta allows
the prostaglandin-deficient embryos to develop normally
(Reese et al., 2000, 2001). Mammalian blastocysts produce
high levels of PGE2 and PGF2a, supporting this idea and
suggesting a critical requirement for these bioactive lipids
during blastocyst development (Davis et al., 1983; Dey et al.,
1980). In agreement, murine blastocysts cultured outside of the
mother do not survive in the presence of COX inhibitors
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University Medical Center). Therefore, understanding the
developmental function of prostaglandins has been hampered
by the lack of a suitable model system.
Zebrafish as a model for dissecting prostaglandin pathway
Recently, FitzGerald and colleagues identified the zebrafish
orthologues of genes encoding COX-1 and COX-2 (Grosser et
al., 2002). Zebrafish cyclooxygenases have also been shown to
be both genetically and functionally equivalent to their
mammalian counterparts. These initial studies extended by our
work have shown that antisense morpholino oligonucleotides
(MOs) translation interference or pharmacologic inhibitors of
COX-1 result in gastrulation arrest, while knockdown of COX-2
fails to produce any discernable phenotype (Cha et al., 2005;
Grosser et al., 2002). This is consistent with our finding that
cox1 transcripts were expressed ubiquitously during gastrula-
tion, while cox2 expression was not detected until the end of the
gastrula period (Cha et al., 2005). This finding also supports the
role of COX-1 as a ‘‘housekeeping’’ enzyme in which a basal
level of prostaglandin is required for normal homeostasis.
Zebrafish are an attractive model system in which to address
the roles of prostaglandins in embryogenesis for many reasons
(Amatruda et al., 2002). Each pair-wise mating gives rise to
hundreds of embryos for study on a weekly basis. Most
importantly for prostaglandin biology, embryogenesis occurs
outside of mother’s body, thus not influenced by maternal
prostaglandins. Moreover embryogenesis can be visualized at
tissue and cellular levels due to the transparency of the
developing embryos; molecular markers are available for
virtually all the tissues. Zebrafish embryos and their chorions
are highly permeable to many drugs, facilitating a temporal
control of inhibition of different enzymes involved inTable 1
Loss-of-function (LOF) phenotypes in mouse and zebrafish
Molecules Mouse Knockout Phenotypes Sp
COX-1(/) Minimal M
COX-1(/) female Prolonged parturition M
COX-2(/) Renal pathology+gastritis M
COX-2(/) female Multiple reproductive defects M
COX-1/ -2(/) Patent ductus arteriosus M
EP2(/) Ovulation and fertilization failure M
Hypertension in High-Salt Diet
, Vasodilatory response to PGE2 M
EP3(/) j Vasodilatory response to PGE2 M
EP4(/) Patent ductus arteriosus M
, Vasodilatory response to PGE2 M
IP(/) j Thrombotic tendency M
TP(/) , Thromboembolism and increased bleeding M
tendency
FP(/) Loss of parturition M
Embryonic phenotypes
COX-1 LOF Gastrulation arrest Ze
Vascular tube formation Ze
COX-2 LOF None Ze
EP4 LOF Decreased cell motility Ze
a The phenotypes in zebrafish were assessed before 24 h post fertilization.prostaglandin signaling. In addition, forward genetic screens
have identified mutations in many developmental pathways,
allowing one to study functional interactions between prosta-
glandin signaling and other developmental pathways.
Blood vessel development
Taking advantage of the extra-embryonic development of
zebrafish embryos, we recently further characterized the
functional requirements for prostaglandins in early develop-
ment. After the period of ubiquitous expression during blastula
and early gastrula stages, cox1 transcripts became restricted to
the posterior intermediate mesoderm during somitogenesis and
to posterior mesodermal organs at 24 h post fertilization (hpf),
including blood vessel and nephric duct (Table 1). Partial
knockdown of COX-1 expression using moderate doses of
MOs or pharmacologic inhibition of its activity after gastru-
lation both resulted in defective vascular tube formation and
shortened intersomitic vessels in the posterior body (Cha et al.,
2005). Using pharmacologic inhibition to identify the critical
time window of COX-1 function in blood vessel development
revealed that COX-1 is required after the 20 somite stage, when
the intermediate cell mass (ICM) undergoes morphogenesis to
form the dorsal artery and posterior cardinal vein (Cha et al.,
2005) (Fig. 2). These findings in zebrafish are consistent with
our data in the human cell culture model in which human
umbilical vein endothelial cells (HUVECs) treated with COX-1
antisense oligonucleotides exhibited defects in endothelial tube
formation (Tsujii et al., 1998), while those treated with COX-2
antisense oligonucleotides did not.
In mammalian systems, mounting evidence supports a
critical requirement for cyclooxygenase and its prostaglandin
products in angiogenesis. During implantation and deciduali-
zation, COX-derived prostaglandins (PGs) are important forecies Reference
ouse Langenbach et al., 1995
ouse Gross et al., 1998
ouse Dinchuk et al., 1995
ouse Lim et al., 1997
ouse Loftin et al., 2001
ouse Kennedy et al., 1999
ouse Kennedy et al., 1999
ouse Audoly et al., 1999
ouse Nguyen et al., 1997
ouse Audoly et al., 1999
ouse Murata et al., 1997
ouse Thomas et al., 1998
ouse Sugimoto et al., 1997
brafisha Grosser et al., 2002
brafisha Cha et al., 2005
brafisha Cha et al., 2005
brafisha, human (cell culture) Our unpublished data, Tsujii et al., 1998
Fig. 2. Inhibition of COX-1 results in defective vascular tube formation after 22 somite stage. Treatment of zebrafish with NSAIDs (indomethacin or sulindac) results
in failure of artery and vein differentiation. Indomethacin treatment results in distention of posterior vasculature at day 1 (A), compared to untreated embryos (C).
Staining with an endothelial cell marker, flk1, reveals absence of mesoderm separating the artery (a) and vein (v) 24 h post fertilization (hpf) in indomethacin-treated
embryos (B), compared to the DMSO control (D). A model depicting the key steps in vascular tube formation from the cross-section view. The temporal requirement
of COX-1 function is after 22 somite stage after angioblast and blood cells migrate to the midline. NT: neural tube; HP: hypochord; DA: dorsal aorta; PCV: posterior
cardinal vein.
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al., 2002). Various studies also indicate that NSAIDs inhibited
angiogenesis in vivo (Majima et al., 1997), primarily by
downregulating PGE2 levels. Additionally, PGE2 upregulated
the production of angiogenic factors (VEGF, bFGF), which are
important for the growth and survival of endothelial cells and
stimulates vascular endothelial cell proliferation, migration,
and tube formation (Iniguez et al., 2003). In zebrafish,
sprouting of the intersomitic vessels from the dorsal aorta
occurs by angiogenesis, whereby angioblasts migrate along the
dorsal aorta from the posterior lateral mesoderm and sprout at
the intersomitic boundaries (Lawson and Weinstein, 2002b). In
embryos in which COX-1 activity was inhibited by indometh-
acin, approximately 70% of the intersomitic vessels were either
shortened or absent at 1 day post-fertilization but somite
differentiation occurred normally (Cha et al., 2005), leading us
to hypothesize that lack or inhibition of COX-1 activity was
responsible for shortened intersomitic vessel formation in
zebrafish, and not by other secondary defects in development
such as somite formation. Zebrafish are an established model
for studying angiogenesis (Lawson and Weinstein, 2002a), the
role of COX-1 signaling in regulating angiogenesis needs to be
further explored in this model system to understand the precise
cellular and molecular mechanisms involved.
Cell motility in gastrulation and cancer metastasis
Over the past decade, COX-2 derived prostaglandins have
been implicated in the development and progression of many
types of cancer (Gupta and Dubois, 2001). One aspect of this
research involves elucidating the mechanisms by which PGE2
signaling promotes cancer cell invasion and movement during
metastasis (Fig. 3). Upon stimulation with PGE2, cancer cells
demonstrated increased proliferation and invasion. Further-
more, the stimulatory effects of PGE2 were dependent upon the
activation of the phosphatidylinositol 3-kinase/Akt pathway
(Sheng et al., 2001), which ultimately induce actin polymeri-zation and, possibly, epithelial–mesenchymal transition, to
cause invasion and migration of cancer cells during metastatic
spread (Fig. 3). However these studies were primarily from
tumor cell lines in vitro and the cellular behavior and molecular
pathways regulated by PGE2 in vivo are not known. PGE2-
induced migration and invasion of cancer cells can also occur
via rapid transactivation and phosphorylation of the epidermal
growth factor receptor (EGFR) both intracellularly (Buchanan
et al., 2003) and extracellularly (Pai et al., 2002), These results
supported the notion that the early effects of COX-2-derived
PGE2 are mediated, in part, by activation of the EGFR, and this
transactivation is responsible for subsequent downstream
effects, including the stimulation of cell migration and invasion.
Assaying the prostaglandin levels in zebrafish embryos
(Cha et al., 2005) and adults (Grosser et al., 2002) revealed the
presence of PGE2, PGI2, PGF2a and low levels of TxA2,
suggesting the existence of prostaglandin synthases and
receptors. In support of this hypothesis, we and others have
recently identified the zebrafish orthologues of microsomal
prostaglandin E2 synthase (mPGES) (Pini et al., 2005) and EP
receptors in zebrafish (YC, LSK, RND, unpublished data).
Moreover using antisense morpholino oligonucleotides to
inhibit the translation and/or splicing of the PGE2 signaling
cascade components we demonstrated that PGE2 regulates cell
movement during gastrulation via the EP4 receptor in zebrafish
(YC, LSK, RND, unpublished data). The similarity between
the cancer cell and zebrafish embryo data is quite striking: both
models imply that PGE2 stimulation of EP4 is the key step in
regulating cell movement, both systems suggest PI3K/Akt as
the key mediator downstream of EP4 signaling, and finally,
both models do not implicate other EP receptors in this process,
demonstrating that PGE2-mediated stimulation of cell move-
ment may be restricted to the EP4 receptor. Additionally in
zebrafish, EP4 signaling primarily promotes cell motility,
without influencing cell shape or directional movement during
gastrulation (YC, LSK and RND, unpublished data). Therefore,
understanding the mechanism by which EP4 activates PI3K/
Fig. 3. Mechanisms of COX-derived PGE2 in carcinogenesis. PGE2 stimulation of EP4 receptor results in invasion and migration of cancer cells. In addition, PGE2
can also stimulate production of proangiogenic factors, such as vascular endothelial growth factor, to promote migration and tube formation of endothelial cells.
Solid malignancies are made up of multiple types of cells that produce signals that work in both a paracrine and autocrine manner as depicted.
Y.I. Cha et al. / Developmental Biology 289 (2006) 263–272270Akt and, furthermore, elucidating how Akt ultimately allows
cell movement to occur in zebrafish may provide insight into
how PGE2 regulates cell movement during metastasis.
Outstanding questions and future directions
Zebrafish is an intriguing and promising model, which may
allow for a clearer understanding of the precise role of
prostaglandins in regulating embryonic development. One
pressing question to address is the unexpected pathology
concerning the cardiovascular side effects found in humans
after prolonged treatment with COX-2 selective inhibitors. In
human studies, COX-2 inhibitors appear to affect the formation
of prostacyclin (McAdam et al., 1999), shifting the balance
toward a prothrombotic state (Cheng et al., 2002). Hence, it
would be important to address whether this also occurs in adult
fish by treating them with a wide variety of COX selective
inhibitors. Many of the same genes involved in blood-vessel
formation and blood cell development in mammals also have
been shown to function in similar ways in zebrafish (Nasevi-
cius et al., 2000). Therefore, we would expect similar
cardiovascular side effects in zebrafish as a result of COX
inhibition. In this case, it would become critical to carefully
quantitate and analyze these cardiovascular defects which may
give insight into the pathophysiology of COX-2 inhibition in
humans.
Another intriguing question to address is the function of
other types of prostaglandins that exist in zebrafish. Our
analysis revealed the presence of EP, IP, and FP receptors in
the zebrafish EST database. Genetic knockdown experiments
and screenings for mutations in genes encoding each
prostaglandin synthase and receptor will undoubtedly providemore insight into how prostaglandins function in early
development. Furthermore, the detailed mechanism by which
prostaglandins signal to downstream effectors warrant further
investigation. We have only begun to uncover some of the
downstream effectors of prostaglandin receptors in mamma-
lian systems. Any downstream targets identified in zebrafish
can be studied in other model systems as well (mouse or
cultured cells) to understand the conserved nature of
prostaglandin signaling. Studies in developmental model
systems have advanced our understanding of major signaling
pathways and, if history provides any indication, studies in
zebrafish will undoubtedly give much insight into the detailed
mechanism for prostaglandin signaling and function. Based
on our findings in zebrafish, it is now important to revisit the
mammalian models to analyze embryonic defects associated
with inhibition of both maternal and fetal production of
prostaglandins.
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